4//SEC Filing
Marshall Keith W 4
Accession 0001209191-23-017435
CIK 0001718852other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 9:33 PM ET
Size
9.4 KB
Accession
0001209191-23-017435
Insider Transaction Report
Form 4
Marshall Keith W
Chief Financial Officer
Transactions
- Sale
Common Stock
2023-03-06$122.13/sh−10,000$1,221,300→ 9,811 total - Exercise/Conversion
Common Stock
2023-03-06$3.70/sh+10,000$37,000→ 19,811 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-03-06−10,000→ 103,040 totalExercise: $3.70Exp: 2030-12-17→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.
Documents
Issuer
Prometheus Biosciences, Inc.
CIK 0001718852
Entity typeother
Related Parties
1- filerCIK 0001714828
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 9:33 PM ET
- Size
- 9.4 KB